Total Payments
$138,047
2024 Payments
$144.95
Companies
11
Transactions
30
Medicare Patients
9,750
Medicare Billing
$909,132
Payment Breakdown by Category
Other$131,534 (95.3%)
Consulting$4,800 (3.5%)
Food & Beverage$919.38 (0.7%)
Travel$608.26 (0.4%)
Research$184.88 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $131,535 | 5 | 95.3% |
| Consulting Fee | $4,800 | 1 | 3.5% |
| Food and Beverage | $919.38 | 19 | 0.7% |
| Travel and Lodging | $608.26 | 3 | 0.4% |
| Unspecified | $184.88 | 2 | 0.1% |
Payments by Type
General
$137,862
28 transactions
Research
$184.88
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $131,607 | 6 | $0 (2023) |
| AbbVie, Inc. | $5,692 | 9 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $184.88 | 2 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $135.41 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $125.00 | 1 | $0 (2018) |
| Amgen Inc. | $81.11 | 1 | $0 (2024) |
| STRATA Skin Sciences, Inc. | $63.84 | 4 | $0 (2024) |
| Celgene Corporation | $50.69 | 2 | $0 (2017) |
| Kerecis Limited | $41.09 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $35.91 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $144.95 | 5 | Amgen Inc. ($81.11) |
| 2023 | $138.40 | 3 | Galderma Laboratories, L.P. ($72.01) |
| 2022 | $41.09 | 1 | Kerecis Limited ($41.09) |
| 2019 | $44,683 | 2 | Galderma Laboratories, L.P. ($44,619) |
| 2018 | $22,279 | 5 | Galderma Laboratories, L.P. ($21,898) |
| 2017 | $70,760 | 14 | Galderma Laboratories, L.P. ($65,018) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $2.73 | General |
| Category: Dermatology | ||||||
| 12/06/2024 | Amgen Inc. | AMJEVITA (Biological), Otezla, WEZLANA | Food and Beverage | In-kind items and services | $81.11 | General |
| Category: Inflammation | ||||||
| 08/26/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Dermatology | ||||||
| 05/30/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: Dermatology | ||||||
| 03/11/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: Dermatology | ||||||
| 08/03/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.48 | General |
| Category: Dermatology | ||||||
| 07/27/2023 | Galderma Laboratories, L.P. | EPSOLAY (Drug), TWYNEO | Food and Beverage | In-kind items and services | $72.01 | General |
| Category: ROSACEA | ||||||
| 06/02/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $35.91 | General |
| Category: Immunology | ||||||
| 08/24/2022 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 GraftGuide | Food and Beverage | Cash or cash equivalent | $41.09 | General |
| Category: Wound Care | ||||||
| 09/11/2019 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Grant | Cash or cash equivalent | $44,619.00 | General |
| Category: ROSACEA | ||||||
| 04/10/2019 | Janssen Scientific Affairs, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $64.18 | General |
| Category: Immunology | ||||||
| 07/16/2018 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Grant | In-kind items and services | $21,898.00 | General |
| Category: ROSACEA | ||||||
| 04/20/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $61.01 | Research |
| Study: Patient-reported Disease Burden in Adults with Atopic Dermatitis in the Clinical Practice Setting and Impact of Inadequately Controlled Disease: A US Cross-sectional Study • Category: IMMUNOLOGY | ||||||
| 03/07/2018 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Drug) | — | In-kind items and services | $123.87 | Research |
| Study: Patient-reported Disease Burden in Adults with Atopic Dermatitis in the Clinical Practice Setting and Impact of Inadequately Controlled Disease: A US Cross-sectional Study • Category: IMMUNOLOGY | ||||||
| 02/16/2018 | Janssen Biotech, Inc. | Tremfya (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 01/08/2018 | Janssen Scientific Affairs, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $71.23 | General |
| Category: Immunology | ||||||
| 10/19/2017 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 10/19/2017 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $25.32 | General |
| 09/08/2017 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Grant | Cash or cash equivalent | $26,771.40 | General |
| Category: ROSACEA | ||||||
| 09/08/2017 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Grant | Cash or cash equivalent | $17,847.60 | General |
| Category: ROSACEA | ||||||
| 07/17/2017 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Dermatology | ||||||
| 06/13/2017 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Grant | In-kind items and services | $20,398.50 | General |
| Category: ROSACEA | ||||||
| 04/21/2017 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $367.48 | General |
| 04/21/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $71.81 | General |
| 04/21/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $42.64 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Patient-reported Disease Burden in Adults with Atopic Dermatitis in the Clinical Practice Setting and Impact of Inadequately Controlled Disease: A US Cross-sectional Study | SANOFI-AVENTIS U.S. LLC | $184.88 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,553 | 5,656 | $993,676 | $218,315 |
| 2022 | 13 | 2,586 | 6,134 | $1.0M | $244,959 |
| 2021 | 13 | 2,472 | 6,111 | $1.0M | $257,079 |
| 2020 | 12 | 2,139 | 4,729 | $808,513 | $188,779 |
Total Patients
9,750
Total Services
22,630
Medicare Billing
$909,132
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 708 | 979 | $249,645 | $68,119 | 27.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 523 | 680 | $190,400 | $29,704 | 15.6% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 136 | 206 | $123,188 | $25,037 | 20.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 224 | 254 | $96,234 | $22,813 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 178 | 217 | $80,073 | $21,425 | 26.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 196 | 221 | $80,318 | $16,752 | 20.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 416 | 2,702 | $83,762 | $14,885 | 17.8% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 13 | 59 | $28,851 | $5,843 | 20.3% |
| 96900 | Application of ultraviolet light to skin | Office | 2023 | 19 | 173 | $17,127 | $3,805 | 22.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 45 | 45 | $16,155 | $3,387 | 21.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 47 | 71 | $13,996 | $3,113 | 22.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $8,944 | $2,113 | 23.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 32 | 33 | $4,983 | $1,320 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 699 | 1,058 | $269,790 | $73,638 | 27.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 521 | 697 | $174,947 | $31,025 | 17.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 145 | 219 | $130,962 | $27,377 | 20.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 236 | 271 | $86,991 | $24,949 | 28.7% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 22 | 228 | $111,492 | $24,604 | 22.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 207 | 241 | $63,383 | $17,963 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 136 | 179 | $66,051 | $17,267 | 26.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 434 | 2,963 | $91,853 | $16,057 | 17.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 74 | 78 | $11,778 | $3,536 | 30.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 38 | 38 | $13,642 | $3,316 | 24.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 41 | 54 | $7,722 | $2,499 | 32.4% |
| 96900 | Application of ultraviolet light to skin | Office | 2022 | 18 | 92 | $9,108 | $1,983 | 21.8% |
About Dr. Tissa Hata, M.D
Dr. Tissa Hata, M.D is a Dermatology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558313916.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tissa Hata, M.D has received a total of $138,047 in payments from pharmaceutical and medical device companies, with $144.95 received in 2024. These payments were reported across 30 transactions from 11 companies. The most common payment nature is "Grant" ($131,535).
As a Medicare-enrolled provider, Hata has provided services to 9,750 Medicare beneficiaries, totaling 22,630 services with total Medicare billing of $909,132. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location San Diego, CA
- Active Since 05/16/2006
- Last Updated 06/08/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1558313916
Products in Payments
- SOOLANTRA (Drug) $131,535
- Tremfya (Drug) $260.41
- DUPIXENT (Drug) $184.88
- AMJEVITA (Biological) $81.11
- EPSOLAY (Drug) $72.01
- XTRAC (Device) $63.84
- Otezla (Drug) $50.69
- Kerecis Omega3 SurgiClose (Device) $41.09
- Sotyktu (Drug) $35.91
- COSENTYX (Drug) $30.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in San Diego
Dr. Sabrina Fabi, M.d, M.D
Dermatology — Payments: $3.3M
Dermatology $3.3M
Neal Bhatia, Md, MD
Dermatology — Payments: $2.6M
Dermatology $2.6M
Dr. Arisa Ortiz, M.d, M.D
Dermatology — Payments: $354,946
Dermatology $354,946
Dr. Dawn Eichenfield, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $179,796
Dermatology $179,796
Michael Bradshaw, M.d, M.D
Dermatology — Payments: $174,743
Dermatology $174,743
Dr. David Chu, M.d, M.D
Dermatology — Payments: $96,502
Dermatology $96,502